Scinai Immunotherapeutics (SCNI) Competitors $3.40 +0.03 (+0.89%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends SCNI vs. APTO, TSBX, BCDA, KLTO, BCLI, COEP, CERO, EVAX, ONVO, and FRTXShould you be buying Scinai Immunotherapeutics stock or one of its competitors? The main competitors of Scinai Immunotherapeutics include Aptose Biosciences (APTO), Turnstone Biologics (TSBX), BioCardia (BCDA), Klotho Neurosciences (KLTO), Brainstorm Cell Therapeutics (BCLI), Coeptis Therapeutics (COEP), CERo Therapeutics (CERO), Evaxion Biotech A/S (EVAX), Organovo (ONVO), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "biological products, except diagnostic" industry. Scinai Immunotherapeutics vs. Aptose Biosciences Turnstone Biologics BioCardia Klotho Neurosciences Brainstorm Cell Therapeutics Coeptis Therapeutics CERo Therapeutics Evaxion Biotech A/S Organovo Fresh Tracks Therapeutics Aptose Biosciences (NASDAQ:APTO) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership. Do institutionals & insiders have more ownership in APTO or SCNI? 26.6% of Aptose Biosciences shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 3.9% of Aptose Biosciences shares are held by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to APTO or SCNI? In the previous week, Aptose Biosciences had 3 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 5 mentions for Aptose Biosciences and 2 mentions for Scinai Immunotherapeutics. Aptose Biosciences' average media sentiment score of 0.09 beat Scinai Immunotherapeutics' score of 0.00 indicating that Aptose Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptose Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Scinai Immunotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, APTO or SCNI? Aptose Biosciences has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Does the MarketBeat Community favor APTO or SCNI? Aptose Biosciences received 380 more outperform votes than Scinai Immunotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformAptose BiosciencesOutperform Votes38063.12% Underperform Votes22236.88% Scinai ImmunotherapeuticsN/AN/A Which has stronger earnings & valuation, APTO or SCNI? Scinai Immunotherapeutics has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptose BiosciencesN/AN/A-$51.21M-$2.97-0.09Scinai Immunotherapeutics$452K6.42-$6.50M-$239.17-0.01 Do analysts rate APTO or SCNI? Aptose Biosciences currently has a consensus target price of $4.33, indicating a potential upside of 1,453.17%. Given Aptose Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than Scinai Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptose Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Scinai Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is APTO or SCNI more profitable? Scinai Immunotherapeutics' return on equity of 0.00% beat Aptose Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aptose BiosciencesN/A -5,683.22% -300.44% Scinai Immunotherapeutics N/A N/A -30.48% SummaryScinai Immunotherapeutics beats Aptose Biosciences on 8 of the 15 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Scinai Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCNI vs. The Competition Export to ExcelMetricScinai ImmunotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.90M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-0.0146.7390.0517.18Price / Sales6.42415.011,116.25117.05Price / CashN/A182.1043.1037.85Price / Book-0.353.894.784.78Net Income-$6.50M-$42.21M$120.31M$225.60M7 Day Performance-0.58%-2.15%-1.92%-1.23%1 Month Performance-3.95%1.73%13.65%0.46%1 Year Performance-50.23%16.36%28.34%15.24% Scinai Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCNIScinai Immunotherapeutics0.2521 of 5 stars$3.40+0.9%N/A-50.7%$2.90M$452,000.00-0.0131APTOAptose Biosciences2.6342 of 5 stars$0.19flat$4.33+2,190.3%-87.7%$11.39MN/A-0.0631News CoverageGap UpTSBXTurnstone Biologics2.8506 of 5 stars$0.47-2.1%$2.13+349.9%-80.2%$10.92M$19.31M-0.1582Positive NewsGap DownBCDABioCardia3.3081 of 5 stars$2.09+0.5%$25.00+1,096.2%-79.8%$9.58M$71,000.00-0.5016Analyst ForecastShort Interest ↓Positive NewsGap UpKLTOKlotho NeurosciencesN/A$0.44+2.3%N/AN/A$9.43MN/A0.00N/AGap DownBCLIBrainstorm Cell Therapeutics3.993 of 5 stars$1.55+6.9%$30.00+1,835.5%-21.2%$8.84MN/A-0.3240Gap UpCOEPCoeptis Therapeutics0.3751 of 5 stars$0.19+5.5%N/A-83.9%$7.85M$80,000.00-0.662Gap UpCEROCERo TherapeuticsN/A$0.05-16.4%N/AN/A$7.67MN/A0.008High Trading VolumeEVAXEvaxion Biotech A/S3.1513 of 5 stars$1.05-7.9%$11.00+947.6%-86.6%$6.16M$3.30M-3.6249ONVOOrganovoN/A$0.39-2.5%N/A-67.6%$6.03M$110,000.000.0020Analyst ForecastFRTXFresh Tracks TherapeuticsN/A$0.75flatN/A-9.8%$4.48M$10.06M-0.5320 Related Companies and Tools Related Companies Aptose Biosciences Alternatives Turnstone Biologics Alternatives BioCardia Alternatives Klotho Neurosciences Alternatives Brainstorm Cell Therapeutics Alternatives Coeptis Therapeutics Alternatives CERo Therapeutics Alternatives Evaxion Biotech A/S Alternatives Organovo Alternatives Fresh Tracks Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SCNI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SCNI Stock Alerts